Bausch Health Companies (BHC) Financials

$4.76 -0.17 (-3.45%)

Closing price 05/6/2025 03:59 PM Eastern

Extended Trading

$4.99 +0.23 (+4.92%)

As of 05:02 AM Eastern

Annual Income Statements for Bausch Health Companies

This table shows Bausch Health Companies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	881	-292	-2,409	2,404	-4,148	-1,788	-6,316	-948	-225	-592	-46
Consolidated Net Income / (Loss)	880	-288	-2,408	2,404	-4,144	-1,783	-559	-937	-212	-611	-72
Net Income / (Loss) Continuing Operations	880	-288	-2,408	2,404	-4,144	-1,783	-6,315	-937	-212	-611	-72
Total Pre-Tax Income	1,054	-155	-2,435	-1,741	-4,154	-1,837	-6,690	-1,024	-129	-390	167
Total Operating Income	2,001	1,527	-566	102	-2,384	-203	676	450	454	963	1,546
Total Gross Profit	6,028	7,915	7,063	6,176	6,029	6,251	0.00	6,040	5,760	6,198	6,843
Total Revenue	8,206	10,447	9,674	8,724	8,380	8,601	0.00	8,434	8,124	8,757	9,625
Operating Revenue	8,206	10,447	9,674	8,724	8,380	8,601	-	8,434	8,124	8,757	9,625
Total Cost of Revenue	2,178	2,532	2,611	2,548	2,351	2,350	0.00	2,394	2,364	2,559	2,782
Operating Cost of Revenue	2,178	2,532	2,611	2,548	2,351	2,350	0.00	2,394	2,364	2,559	2,782
Total Operating Expenses	4,027	6,388	7,629	6,074	8,413	6,454	5,080	5,590	5,306	5,235	5,297
Selling, General & Admin Expense	2,026	2,700	2,810	2,582	2,473	2,554	2,367	2,624	2,625	2,917	3,296
Research & Development Expense	266	440	455	361	413	471	452	465	529	604	616
Amortization Expense	1,427	2,257	2,673	2,690	2,644	1,897	1,645	1,375	1,215	1,077	1,077
Other Operating Expenses / (Income)	-219	325	60	-637	-29	1,426	502	373	35	28	247
Impairment Charge	145	304	1,499	1,026	2,890	75	114	703	839	547	29
Restructuring Charge	382	362	132	52	22	31	-	50	63	62	32
Total Other Income / (Expense), net	-947	-1,682	-1,869	-1,843	-1,770	-1,634	-1,610	-1,474	-583	-1,353	-1,379
Interest Expense	1,101	1,583	1,836	1,962	1,804	1,654	1,593	1,488	589	1,327	1,365
Interest & Investment Income	298	4.00	8.00	12	11	12	13	7.00	14	26	33
Other Income / (Expense), net	-144	-103	-41	107	23	8.00	-30	7.00	-8.00	-52	-47
Income Tax Expense	174	133	-27	-4,145	-10	-54	-375	-87	83	221	239
Net Income / (Loss) Attributable to Noncontrolling Interest	-1.00	4.00	1.00	0.00	4.00	5.00	1.00	11	13	-19	-26
Basic Earnings per Share	$2.63	($0.85)	($6.94)	$6.86	($11.81)	($5.08)	($1.58)	($2.64)	($0.62)	($1.62)	($0.13)
Weighted Average Basic Shares Outstanding	335.40M	342.70M	347.30M	350.20M	351.30M	352.10M	355M	358.90M	362M	364.90M	368M
Diluted Earnings per Share	$2.58	($0.85)	($6.94)	$6.83	($11.81)	($5.08)	($1.58)	($2.64)	($0.62)	($1.62)	($0.13)
Weighted Average Diluted Shares Outstanding	341.50M	342.70M	347.30M	351.80M	351.30M	352.10M	355M	358.90M	362M	364.90M	368M
Weighted Average Basic & Diluted Shares Outstanding	323.80M	343.50M	347.10M	350.40M	351.30M	352.10M	355M	359.65M	362.04M	365.41M	367.93M

This table shows Bausch Health Companies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	399	-410	-201	26	-378	-39	-64	10	-85	93	-58
Consolidated Net Income / (Loss)	403	-410	-209	27	-382	-47	-77	-1.00	-92	98	-86
Net Income / (Loss) Continuing Operations	403	-410	-209	27	-382	-47	-77	-1.00	-92	98	-86
Total Pre-Tax Income	439	-357	-136	79	-326	-7.00	-69	48	-21	209	-47
Total Operating Income	244	-236	175	412	14	362	281	389	318	558	276
Total Gross Profit	1,462	1,541	1,362	1,518	1,615	1,703	1,513	1,684	1,814	1,832	1,558
Total Revenue	2,046	2,193	1,944	2,167	2,238	2,408	2,153	2,403	2,510	2,559	2,259
Operating Revenue	2,046	2,193	1,944	2,167	2,238	2,408	2,153	2,403	2,510	2,559	2,259
Total Cost of Revenue	584	652	582	649	623	705	640	719	696	727	701
Operating Cost of Revenue	584	652	582	649	623	705	640	719	696	727	701
Total Operating Expenses	1,218	1,777	1,187	1,106	1,601	1,341	1,232	1,295	1,496	1,274	1,282
Selling, General & Admin Expense	661	666	725	711	715	766	794	832	850	820	867
Research & Development Expense	133	142	143	156	153	152	151	156	146	163	143
Amortization Expense	290	313	273	269	253	282	274	270	274	259	256
Other Operating Expenses / (Income)	4.00	29	23	-83	60	28	0.00	20	225	2.00	15
Impairment Charge	120	622	13	37	406	91	1.00	5.00	0.00	23	0.00
Restructuring Charge	10	5.00	10	16	14	22	12	12	1.00	7.00	1.00
Total Other Income / (Expense), net	195	-121	-311	-333	-340	-369	-350	-341	-339	-349	-323
Interest Expense	-185	115	307	319	339	362	344	338	346	337	330
Interest & Investment Income	3.00	6.00	6.00	7.00	6.00	7.00	9.00	8.00	7.00	9.00	11
Other Income / (Expense), net	7.00	-12	-10	-21	-7.00	-14	-15	-11	0.00	-21	-4.00
Income Tax Expense	36	53	73	52	56	40	8.00	49	71	111	39
Net Income / (Loss) Attributable to Noncontrolling Interest	4.00	-	-8.00	1.00	-4.00	-8.00	-13	-11	-7.00	5.00	-28
Basic Earnings per Share	$1.10	($1.13)	($0.55)	$0.07	($1.03)	($0.11)	($0.17)	$0.03	($0.23)	$0.24	($0.16)
Weighted Average Basic Shares Outstanding	362.50M	362M	363.30M	364.80M	365.40M	364.90M	366.80M	367.90M	368.40M	368M	369.60M
Diluted Earnings per Share	$1.10	($1.13)	($0.55)	$0.07	($1.03)	($0.11)	($0.17)	$0.03	($0.23)	$0.24	($0.16)
Weighted Average Diluted Shares Outstanding	363.40M	362M	363.30M	367.10M	365.40M	364.90M	366.80M	370.20M	368.40M	368M	369.60M
Weighted Average Basic & Diluted Shares Outstanding	361.87M	362.04M	363.72M	364.33M	365.20M	365.41M	366.80M	367.10M	367.80M	367.93M	369.55M

This table details how cash moves in and out of Bausch Health Companies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-277	274	-55	255	-48	2,521	-1,428	303	-1,528	371	239
Net Cash From Operating Activities	2,312	2,257	2,087	2,290	1,501	1,501	1,111	1,426	-728	1,032	1,597
Net Cash From Continuing Operating Activities	2,312	2,257	2,087	2,290	1,501	1,501	1,111	1,426	-728	1,032	1,597
Net Income / (Loss) Continuing Operations	880	-288	-2,408	2,404	-4,144	-1,783	-559	-937	-212	-611	-72
Consolidated Net Income / (Loss)	880	-288	-2,408	2,404	-4,144	-1,783	-559	-937	-212	-611	-72
Depreciation Expense	1,614	2,467	2,866	2,858	2,819	2,075	1,825	1,552	1,394	1,264	1,267
Amortization Expense	70	145	118	151	79	63	61	55	99	88	137
Non-Cash Adjustments To Reconcile Net Income	312	761	1,857	419	2,873	1,694	625	1,109	-1,437	822	192
Changes in Operating Assets and Liabilities, net	-564	-828	-346	-3,542	-126	-548	-841	-353	-572	-531	73
Net Cash From Investing Activities	-100	-15,577	-125	2,887	-196	-419	-261	409	-303	-2,145	-454
Net Cash From Continuing Investing Activities	-100	-15,577	-125	2,887	-196	-419	-261	409	-303	-2,145	-454
Purchase of Property, Plant & Equipment	-292	-235	-235	-171	-157	-270	-302	-269	-218	-215	-337
Acquisitions	-1,357	-15,526	-86	-165	-78	-188	-7.00	-14	-50	-57	-3.00
Purchase of Investments	-72	-49	-1.00	-7.00	-7.00	-16	-4.00	-19	-62	-1,917	-148
Divestitures	76	0.00	199	3,253	39	45	21	669	5.00	5.00	7.00
Sale and/or Maturity of Investments	53	251	17	2.00	7.00	10	8.00	15	22	26	14
Other Investing Activities, net	0.00	-31	-19	-25	0.00	0.00	23	27	0.00	13	13
Net Cash From Financing Activities	-2,460	13,624	-1,963	-4,963	-1,353	1,443	-2,294	-1,513	-474	1,475	-868
Net Cash From Continuing Financing Activities	-2,460	13,624	-1,963	-4,963	-1,353	1,443	-2,294	-1,513	-474	1,475	-868
Repayment of Debt	-3,968	-5,289	-2,545	-14,339	-10,232	-4,454	-5,684	-3,478	-7,928	-1,757	-1,476
Issuance of Debt	1,649	17,825	1,223	9,425	8,944	5,972	3,455	2,100	6,836	3,291	661
Other Financing Activities, net	-133	-264	-641	-49	-65	-75	-65	-135	618	-59	-53
Effect of Exchange Rate Changes	-29	-30	-54	41	-	-4.00	16	-19	-23	9.00	-36

This table details how cash moves in and out of Bausch Health Companies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	-1,382	94	-60	57	192	182	-207	-132	127	451	-44
Net Cash From Operating Activities	-1,263	475	154	206	282	390	211	380	405	601	211
Net Cash From Continuing Operating Activities	-1,263	475	154	206	282	390	211	380	405	601	211
Net Income / (Loss) Continuing Operations	403	-410	-209	27	-382	-47	-77	-1.00	-92	98	-86
Consolidated Net Income / (Loss)	403	-410	-209	27	-382	-47	-77	-1.00	-92	98	-86
Depreciation Expense	335	360	319	315	301	329	320	318	322	307	305
Amortization Expense	22	13	11	12	28	37	34	34	34	35	37
Non-Cash Adjustments To Reconcile Net Income	-1,658	515	94	85	486	157	26	41	18	107	29
Changes in Operating Assets and Liabilities, net	-365	-3.00	-61	-233	-151	-86	-92	-12	123	54	-74
Net Cash From Investing Activities	-53	-136	-78	-30	-1,889	-148	-73	-79	-102	-200	-130
Net Cash From Continuing Investing Activities	-53	-136	-78	-30	-1,889	-148	-73	-79	-102	-200	-130
Purchase of Property, Plant & Equipment	-54	-66	-47	-28	-42	-98	-82	-78	-71	-106	-115
Acquisitions	-5.00	-30	-4.00	-3.00	-4.00	-46	-1.00	-1.00	-	-1.00	-9.00
Purchase of Investments	-1.00	-47	-44	2.00	-1,858	-17	-3.00	-2.00	-47	-96	-16
Divestitures	-	5.00	0.00	1.00	4.00	-	1.00	1.00	5.00	-	0.00
Sale and/or Maturity of Investments	7.00	2.00	11	-2.00	4.00	13	6.00	1.00	4.00	3.00	4.00
Other Investing Activities, net	-	-	6.00	-	7.00	-	6.00	-	7.00	-	6.00
Net Cash From Financing Activities	-36	-276	-142	-120	1,816	-79	-340	-424	-189	85	-146
Net Cash From Continuing Financing Activities	-36	-276	-142	-120	1,816	-79	-340	-424	-189	85	-146
Repayment of Debt	-190	-623	-278	-413	-860	-206	-394	-495	-176	-411	-173
Issuance of Debt	161	355	155	300	2,690	146	75	80	-	506	50
Other Financing Activities, net	-7.00	-8.00	-19	-7.00	-14	-19	-21	-9.00	-13	-10	-23
Effect of Exchange Rate Changes	-30	31	6.00	1.00	-17	19	-5.00	-9.00	13	-35	21

This table presents Bausch Health Companies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	26,305	48,965	43,529	37,497	32,492	33,863	31,199	29,202	25,686	27,350	26,523
Total Current Assets	4,132	5,507	5,077	4,746	4,211	6,969	5,342	5,607	4,247	5,596	5,774
Cash & Equivalents	323	597	542	720	721	3,243	605	582	564	947	1,181
Restricted Cash	-	-	0.00	77	2.00	1.00	1,211	1,537	-	15	20
Accounts Receivable	2,076	2,687	2,517	2,130	1,865	1,839	1,577	1,775	1,790	1,998	2,140
Inventories, net	889	1,257	1,061	1,048	934	1,107	1,094	993	1,090	1,544	1,595
Prepaid Expenses	651	963	696	771	689	779	855	720	776	1,092	838
Plant, Property, & Equipment, net	1,312	1,442	1,312	1,403	1,353	1,466	1,567	1,598	1,600	1,707	1,780
Total Noncurrent Assets	20,861	42,016	37,140	31,348	26,928	25,428	24,290	21,997	19,839	20,047	18,969
Goodwill	9,361	18,553	15,794	15,593	13,142	13,126	13,044	12,457	11,547	11,183	11,087
Intangible Assets	11,278	23,083	18,884	15,211	12,001	10,201	8,445	6,948	5,800	6,456	5,551
Noncurrent Deferred & Refundable Income Taxes	54	156	146	433	1,676	1,690	2,137	2,252	2,166	2,101	1,968
Other Noncurrent Operating Assets	167	224	184	111	109	411	664	340	326	307	363
Total Liabilities & Shareholders' Equity	26,305	48,965	43,529	37,497	32,492	33,863	31,199	29,202	25,686	27,350	26,523
Total Liabilities	20,903	42,936	40,271	31,553	29,677	32,727	30,594	29,236	25,426	27,432	26,845
Total Current Liabilities	2,708	5,313	3,609	4,268	3,836	6,248	4,913	5,198	3,941	4,302	6,752
Short-Term Debt	143	1,020	1.00	209	228	1,234	-	0.00	432	450	2,674
Accounts Payable	398	434	324	365	411	503	337	407	521	719	656
Accrued Expenses	2,157	3,859	3,227	3,694	3,197	4,511	4,576	4,791	2,988	3,133	3,422
Total Noncurrent Liabilities	18,195	37,623	36,662	27,285	25,841	26,479	25,681	24,038	21,485	23,130	20,093
Long-Term Debt	15,228	30,265	29,845	25,235	24,077	24,661	23,925	22,654	20,334	21,938	18,942
Noncurrent Deferred & Payable Income Tax Liabilities	2,324	6,023	5,434	1,180	885	705	528	529	202	163	128
Other Noncurrent Operating Liabilities	403	1,144	1,326	870	879	1,113	1,228	855	949	1,029	1,023
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	5,402	6,029	3,258	5,944	2,815	1,136	605	-34	260	-82	-322
Total Preferred & Common Equity	5,279	5,910	3,152	5,849	2,733	1,063	535	-106	-692	-1,022	-1,279
Total Common Equity	5,279	5,910	3,152	5,849	2,733	1,063	535	-106	-692	-1,022	-1,279
Common Stock	8,593	10,202	10,389	10,470	10,534	10,601	10,681	10,779	10,550	10,637	10,724
Retained Earnings	-2,398	-2,750	-5,129	-2,725	-5,664	-7,452	-8,013	-8,961	-9,186	-9,778	-9,824
Accumulated Other Comprehensive Income / (Loss)	-916	-1,542	-2,108	-1,896	-2,137	-2,086	-2,133	-1,924	-2,056	-1,881	-2,179
Noncontrolling Interest	122	119	106	95	82	73	70	72	952	940	957

This table presents Bausch Health Companies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	26,298	25,445	25,503	27,064	26,913	26,495	26,540	26,421
Total Current Assets	4,010	4,237	4,461	5,048	5,396	5,211	5,351	5,732
Cash & Equivalents	486	518	579	760	733	595	719	1,134
Restricted Cash	11	13	9.00	20	22	28	31	23
Accounts Receivable	1,739	1,688	1,743	1,948	2,048	2,102	2,094	2,072
Inventories, net	1,056	1,222	1,240	1,272	1,636	1,612	1,655	1,613
Prepaid Expenses	718	796	890	1,048	957	874	852	890
Plant, Property, & Equipment, net	1,507	1,596	1,599	1,584	1,713	1,738	1,789	1,882
Total Noncurrent Assets	20,781	19,612	19,443	20,432	19,804	19,546	19,400	18,807
Goodwill	12,044	11,579	11,628	11,187	11,160	11,127	11,171	11,153
Intangible Assets	6,024	5,552	5,299	6,728	6,183	5,903	5,652	5,297
Noncurrent Deferred & Refundable Income Taxes	2,372	2,163	2,191	2,189	2,149	2,187	2,188	1,977
Other Noncurrent Operating Assets	341	318	325	328	312	329	389	380
Total Liabilities & Shareholders' Equity	26,298	25,445	25,503	27,064	26,913	26,495	26,540	26,421
Total Liabilities	25,865	25,300	25,232	27,299	27,087	26,722	26,782	26,661
Total Current Liabilities	3,831	3,923	3,967	4,224	4,405	4,369	4,506	4,256
Short-Term Debt	411	446	444	536	538	452	453	282
Accounts Payable	486	561	515	569	642	579	667	620
Accrued Expenses	2,934	2,916	3,008	3,119	3,225	3,338	3,386	3,354
Total Noncurrent Liabilities	22,034	21,377	21,265	23,075	22,682	22,353	22,028	22,405
Long-Term Debt	20,804	20,207	20,108	21,894	21,536	21,208	21,054	21,228
Noncurrent Deferred & Payable Income Tax Liabilities	422	205	215	213	170	170	169	134
Other Noncurrent Operating Liabilities	808	965	942	968	976	975	805	1,043
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	433	145	271	-235	-174	-227	-242	-240
Total Preferred & Common Equity	-525	-800	-663	-1,180	-1,115	-1,175	-1,174	-1,183
Total Common Equity	-525	-800	-663	-1,180	-1,115	-1,175	-1,174	-1,183
Common Stock	10,516	10,576	10,600	10,610	10,644	10,664	10,690	10,728
Retained Earnings	-8,776	-9,387	-9,361	-9,739	-9,842	-9,832	-9,917	-9,882
Accumulated Other Comprehensive Income / (Loss)	-2,265	-1,989	-1,902	-2,051	-1,917	-2,007	-1,947	-2,029
Noncontrolling Interest	958	945	934	945	941	948	932	943

This table displays calculated financial ratios and metrics derived from Bausch Health Companies' official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	42.23%	27.31%	-7.40%	-9.82%	-3.94%	2.64%	-100.00%	0.00%	-3.68%	7.79%	9.91%
EBITDA Growth	109.97%	13.98%	-41.11%	35.38%	-83.31%	261.83%	30.31%	-18.48%	-6.06%	16.71%	28.28%
EBIT Growth	543.30%	-23.32%	-142.63%	134.43%	-1,229.67%	91.74%	431.28%	-29.26%	-2.41%	104.26%	64.54%
NOPAT Growth	682.82%	-36.02%	-137.07%	118.02%	-2,437.25%	91.48%	433.00%	-33.43%	0.89%	112.11%	-198.88%
Net Income Growth	201.90%	-132.73%	-736.11%	199.83%	-272.38%	56.97%	68.65%	-67.62%	77.37%	-188.21%	88.22%
EPS Growth	195.56%	-132.95%	-716.47%	198.42%	-272.91%	56.99%	68.90%	-67.09%	76.52%	-161.29%	91.98%
Operating Cash Flow Growth	121.88%	-2.38%	-7.53%	9.73%	-34.45%	0.00%	-25.98%	28.35%	-151.05%	241.76%	54.75%
Free Cash Flow Firm Growth	138.80%	-557.67%	139.71%	-103.92%	1,167.29%	-2.27%	-37.35%	63.50%	-85.89%	-158.27%	381.13%
Invested Capital Growth	-7.46%	79.53%	-17.52%	1.02%	-13.71%	-9.89%	-4.51%	-9.74%	-0.19%	4.31%	-5.86%
Revenue Q/Q Growth	1.97%	5.40%	-3.54%	-2.68%	-0.50%	1.21%	-100.00%	1,889.15%	2,746.25%	2.52%	1.59%
EBITDA Q/Q Growth	7.76%	-0.47%	-1.74%	-7.82%	4.88%	-37.52%	66.25%	17.27%	-24.05%	35.19%	6.03%
EBIT Q/Q Growth	19.79%	-20.23%	-10.61%	-66.07%	12.33%	-121.31%	252.00%	437.65%	-57.81%	189.21%	14.43%
NOPAT Q/Q Growth	-12.96%	-39.86%	-3.04%	-82.23%	12.71%	-122.61%	271.14%	476.92%	-57.05%	163.84%	-170.53%
Net Income Q/Q Growth	74.92%	-147.96%	-5.49%	74.20%	-25.96%	-193.26%	70.95%	19.29%	-178.52%	37.27%	66.82%
EPS Q/Q Growth	85.61%	-148.85%	-5.63%	76.03%	-25.77%	-191.95%	71.01%	19.51%	-186.11%	38.64%	72.92%
Operating Cash Flow Q/Q Growth	31.45%	-9.46%	-3.92%	2.97%	-14.72%	-5.36%	16.82%	-20.60%	38.25%	-7.61%	15.22%
Free Cash Flow Firm Q/Q Growth	9.01%	-12.89%	306.88%	-105.82%	69.33%	6.16%	-23.17%	-7.93%	487.41%	-2,345.88%	-63.40%
Invested Capital Q/Q Growth	-1.16%	2.19%	-11.09%	0.63%	-2.22%	-5.98%	-1.29%	0.90%	-3.26%	-0.33%	-3.23%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	73.46%	75.76%	73.01%	70.79%	71.95%	72.68%	0.00%	71.61%	70.90%	70.78%	71.10%
EBITDA Margin	43.15%	38.63%	24.57%	36.89%	6.41%	22.59%	0.00%	24.47%	23.87%	25.84%	30.16%
Operating Margin	24.38%	14.62%	-5.85%	1.17%	-28.45%	-2.36%	0.00%	5.34%	5.59%	11.00%	16.06%
EBIT Margin	22.63%	13.63%	-6.27%	2.40%	-28.17%	-2.27%	0.00%	5.42%	5.49%	10.40%	15.57%
Profit (Net Income) Margin	10.72%	-2.76%	-24.89%	27.56%	-49.45%	-20.73%	0.00%	-11.11%	-2.61%	-6.98%	-0.75%
Tax Burden Percent	83.49%	185.81%	98.89%	-138.08%	99.76%	97.06%	8.36%	91.50%	164.34%	156.67%	-43.11%
Interest Burden Percent	56.76%	-10.88%	401.15%	-833.01%	175.94%	942.05%	-1,035.60%	-224.07%	-28.92%	-42.81%	11.14%
Effective Tax Rate	16.51%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	143.11%
Return on Invested Capital (ROIC)	7.85%	3.74%	-1.18%	0.23%	-5.86%	-0.57%	0.00%	1.46%	1.55%	3.22%	-3.22%
ROIC Less NNEP Spread (ROIC-NNEP)	2.90%	-2.19%	-8.15%	9.26%	-16.12%	-7.66%	0.00%	-4.41%	-1.05%	-2.95%	-0.38%
Return on Net Nonoperating Assets (RNNOA)	8.70%	-8.78%	-50.67%	52.01%	-88.77%	-89.69%	0.00%	-329.65%	-189.16%	-689.74%	38.86%
Return on Equity (ROE)	16.55%	-5.04%	-51.86%	52.25%	-94.62%	-90.26%	-64.22%	-328.20%	-187.61%	-686.52%	35.64%
Cash Return on Invested Capital (CROIC)	15.61%	-53.16%	18.02%	-0.78%	8.86%	9.84%	6.65%	11.70%	1.74%	-0.99%	2.82%
Operating Return on Assets (OROA)	6.84%	3.78%	-1.31%	0.52%	-6.75%	-0.59%	0.00%	1.51%	1.63%	3.44%	5.56%
Return on Assets (ROA)	3.24%	-0.77%	-5.21%	5.93%	-11.84%	-5.37%	0.00%	-3.10%	-0.77%	-2.30%	-0.27%
Return on Common Equity (ROCE)	16.18%	-4.93%	-50.60%	51.11%	-92.71%	-86.71%	-58.94%	-246.58%	662.45%	6,610.62%	203.01%
Return on Equity Simple (ROE_SIMPLE)	16.67%	-4.87%	-76.40%	41.10%	-151.63%	-167.73%	-104.49%	883.96%	30.64%	59.78%	5.63%
Net Operating Profit after Tax (NOPAT)	1,671	1,069	-396	71	-1,669	-142	473	315	318	674	-667
NOPAT Margin	20.36%	10.23%	-4.10%	0.82%	-19.91%	-1.65%	0.00%	3.73%	3.91%	7.70%	-6.93%
Net Nonoperating Expense Percent (NNEP)	4.96%	5.93%	6.97%	-9.03%	10.26%	7.10%	4.61%	5.87%	2.60%	6.17%	-2.84%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	1.51%	3.02%	-3.13%
Cost of Revenue to Revenue	26.54%	24.24%	26.99%	29.21%	28.05%	27.32%	0.00%	28.39%	29.10%	29.22%	28.90%
SG&A Expenses to Revenue	24.69%	25.84%	29.05%	29.60%	29.51%	29.69%	0.00%	31.11%	32.31%	33.31%	34.24%
R&D to Revenue	3.24%	4.21%	4.70%	4.14%	4.93%	5.48%	0.00%	5.51%	6.51%	6.90%	6.40%
Operating Expenses to Revenue	49.07%	61.15%	78.86%	69.62%	100.39%	75.04%	0.00%	66.28%	65.31%	59.78%	55.03%
Earnings before Interest and Taxes (EBIT)	1,857	1,424	-607	209	-2,361	-195	646	457	446	911	1,499
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3,541	4,036	2,377	3,218	537	1,943	2,532	2,064	1,939	2,263	2,903
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	9.10	5.90	1.60	1.24	2.36	9.92	13.81	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	5.85	3.34	0.52	0.83	0.77	1.23	0.00	1.18	0.28	0.33	0.31
Price to Earnings (P/E)	54.53	0.00	0.00	3.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.83%	0.00%	0.00%	33.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.09	1.79	1.14	1.05	1.14	1.40	1.30	1.49	1.14	1.19	1.21
Enterprise Value to Revenue (EV/Rev)	7.70	6.29	3.56	3.67	3.59	3.87	0.00	3.62	2.88	2.89	2.53
Enterprise Value to EBITDA (EV/EBITDA)	17.85	16.27	14.50	9.94	56.10	17.12	11.68	14.79	12.08	11.18	8.38
Enterprise Value to EBIT (EV/EBIT)	34.04	46.13	0.00	153.04	0.00	0.00	45.77	66.80	52.53	27.77	16.24
Enterprise Value to NOPAT (EV/NOPAT)	37.83	61.45	0.00	447.98	0.00	0.00	62.48	96.91	73.71	37.52	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	27.34	29.10	16.51	13.97	20.07	22.16	26.61	21.41	0.00	24.51	15.24
Enterprise Value to Free Cash Flow (EV/FCFF)	19.04	0.00	5.71	0.00	11.93	13.48	19.12	12.08	65.66	0.00	41.64
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.85	5.19	9.16	4.28	8.63	22.79	39.55	-666.29	79.87	-273.02	-67.13
Long-Term Debt to Equity	2.82	5.02	9.16	4.25	8.55	21.71	39.55	-666.29	78.21	-267.54	-58.83
Financial Leverage	3.00	4.00	6.21	5.62	5.51	11.70	25.71	74.68	180.25	233.87	-103.57
Leverage Ratio	5.10	6.58	9.96	8.81	7.99	16.79	37.37	105.78	242.87	297.96	-133.35
Compound Leverage Factor	2.90	-0.72	39.95	-73.35	14.06	158.21	-387.01	-237.02	-70.25	-127.55	-14.86
Debt to Total Capital	74.00%	83.84%	90.16%	81.06%	89.62%	95.80%	97.53%	100.15%	98.76%	100.37%	101.51%
Short-Term Debt to Total Capital	0.69%	2.73%	0.00%	0.67%	0.84%	4.57%	0.00%	0.00%	2.05%	2.02%	12.56%
Long-Term Debt to Total Capital	73.31%	81.11%	90.16%	80.40%	88.78%	91.23%	97.53%	100.15%	96.71%	98.35%	88.95%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.59%	0.32%	0.32%	0.30%	0.30%	0.27%	0.29%	0.32%	4.53%	4.21%	4.49%
Common Equity to Total Capital	25.42%	15.84%	9.52%	18.63%	10.08%	3.93%	2.18%	-0.47%	-3.29%	-4.58%	-6.01%
Debt to EBITDA	4.34	7.75	12.56	7.91	45.26	13.33	9.45	10.98	10.71	9.89	7.45
Net Debt to EBITDA	4.25	7.60	12.33	7.66	43.91	11.66	8.73	9.95	10.42	9.47	7.03
Long-Term Debt to EBITDA	4.30	7.50	12.56	7.84	44.84	12.69	9.45	10.98	10.49	9.69	6.53
Debt to NOPAT	9.20	29.27	-75.33	356.36	-14.56	-182.23	50.56	71.92	65.34	33.21	-32.43
Net Debt to NOPAT	9.01	28.71	-73.96	345.20	-14.13	-159.40	46.72	65.19	63.57	31.78	-30.63
Long-Term Debt to NOPAT	9.11	28.31	-75.33	353.43	-14.43	-173.55	50.56	71.92	63.98	32.54	-28.42
Altman Z-Score	1.86	0.72	0.13	0.30	-0.08	0.15	-0.13	0.13	-0.06	0.05	0.05
Noncontrolling Interest Sharing Ratio	2.23%	2.11%	2.42%	2.18%	2.02%	3.92%	8.21%	24.87%	453.10%	1,062.92%	-469.55%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.53	1.04	1.41	1.11	1.10	1.12	1.09	1.08	1.08	1.30	0.86
Quick Ratio	0.89	0.62	0.85	0.67	0.67	0.81	0.44	0.45	0.60	0.68	0.49
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	3,320	-15,195	6,035	-237	2,525	2,468	1,546	2,528	357	-208	584
Operating Cash Flow to CapEx	0.00%	1,016.67%	888.09%	1,339.18%	956.05%	555.93%	367.88%	530.11%	-333.95%	480.00%	473.89%
Free Cash Flow to Firm to Interest Expense	3.02	-9.60	3.29	-0.12	1.40	1.49	0.97	1.70	0.61	-0.16	0.43
Operating Cash Flow to Interest Expense	2.10	1.43	1.14	1.17	0.83	0.91	0.70	0.96	-1.24	0.78	1.17
Operating Cash Flow Less CapEx to Interest Expense	3.19	1.29	1.01	1.08	0.75	0.74	0.51	0.78	-1.61	0.62	0.92
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.30	0.28	0.21	0.22	0.24	0.26	0.00	0.28	0.30	0.33	0.36
Accounts Receivable Turnover	4.37	4.39	3.72	3.75	4.20	4.64	0.00	5.03	4.56	4.62	4.65
Inventory Turnover	2.46	2.36	2.25	2.42	2.37	2.30	0.00	2.29	2.27	1.94	1.77
Fixed Asset Turnover	6.44	7.59	7.03	6.43	6.08	6.10	0.00	5.33	5.08	5.30	5.52
Accounts Payable Turnover	6.01	6.09	6.89	7.40	6.06	5.14	0.00	6.44	5.09	4.13	4.05
Days Sales Outstanding (DSO)	83.45	83.20	98.17	97.21	87.00	78.59	0.00	72.53	80.09	78.94	78.46
Days Inventory Outstanding (DIO)	148.50	154.69	162.02	151.06	153.86	158.50	0.00	159.10	160.81	187.85	205.92
Days Payable Outstanding (DPO)	60.75	59.97	52.98	49.35	60.24	70.98	0.00	56.72	71.64	88.43	90.20
Cash Conversion Cycle (CCC)	171.20	177.93	207.21	198.92	180.62	166.12	0.00	174.91	169.25	178.36	194.18
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	20,450	36,714	30,283	30,591	26,397	23,787	22,714	20,501	20,462	21,344	20,093
Invested Capital Turnover	0.39	0.37	0.29	0.29	0.29	0.34	0.00	0.39	0.40	0.42	0.46
Increase / (Decrease) in Invested Capital	-1,650	16,264	-6,431	308	-4,194	-2,610	-1,073	-2,213	-39	882	-1,251
Enterprise Value (EV)	63,209	65,683	34,458	31,986	30,125	33,269	29,566	30,528	23,427	25,295	24,336
Market Capitalization	48,038	34,876	5,048	7,244	6,461	10,545	7,387	9,921	2,273	2,929	2,964
Book Value per Share	$15.73	$17.23	$9.07	$16.78	$7.81	$3.02	$1.51	($0.30)	($1.91)	($2.80)	($3.48)
Tangible Book Value per Share	($45.76)	($104.13)	($90.68)	($71.59)	($64.07)	($63.17)	($59.00)	($54.30)	($49.85)	($51.10)	($48.71)
Total Capital	20,772	37,314	33,104	31,388	27,120	27,031	24,530	22,620	21,026	22,306	21,294
Total Debt	15,371	31,285	29,846	25,444	24,305	25,895	23,925	22,654	20,766	22,388	21,616
Total Long-Term Debt	15,228	30,265	29,845	25,235	24,077	24,661	23,925	22,654	20,334	21,938	18,942
Net Debt	15,048	30,688	29,304	24,647	23,582	22,651	22,109	20,535	20,202	21,426	20,415
Capital Expenditures (CapEx)	-1,200	222	235	171	157	270	302	269	218	215	337
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,243	617	927	-110	-120	-1,289	-1,387	-1,710	174	782	495
Debt-free Net Working Capital (DFNWC)	1,566	1,214	1,469	687	603	1,955	429	409	738	1,744	1,696
Net Working Capital (NWC)	1,423	194	1,468	478	375	721	429	409	306	1,294	-978
Net Nonoperating Expense (NNE)	791	1,357	2,012	-2,333	2,475	1,641	1,032	1,252	530	1,285	-595
Net Nonoperating Obligations (NNO)	15,048	30,685	27,025	24,647	23,582	22,651	22,109	20,535	20,202	21,426	20,415
Total Depreciation and Amortization (D&A)	1,684	2,612	2,984	3,009	2,898	2,138	1,886	1,607	1,493	1,352	1,404
Debt-free, Cash-free Net Working Capital to Revenue	15.15%	5.91%	9.58%	-1.26%	-1.43%	-14.99%	0.00%	-20.28%	2.14%	8.93%	5.14%
Debt-free Net Working Capital to Revenue	19.08%	11.62%	15.19%	7.87%	7.20%	22.73%	0.00%	4.85%	9.08%	19.92%	17.62%
Net Working Capital to Revenue	17.34%	1.86%	15.17%	5.48%	4.47%	8.38%	0.00%	4.85%	3.77%	14.78%	-10.16%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$2.72	($0.85)	($6.94)	$6.86	($11.81)	($5.08)	($1.58)	($2.64)	($0.62)	($1.62)	($0.13)
Adjusted Weighted Average Basic Shares Outstanding	335.40M	342.70M	347.30M	350.20M	351.30M	352.10M	355.62M	358.90M	362M	364.90M	368M
Adjusted Diluted Earnings per Share	$2.67	($0.85)	($6.94)	$6.83	($11.81)	($5.08)	($1.58)	($2.64)	($0.62)	($1.62)	($0.13)
Adjusted Weighted Average Diluted Shares Outstanding	341.50M	342.70M	347.30M	351.80M	351.30M	352.10M	355.62M	358.90M	362M	364.90M	368M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	($5.08)	($1.58)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	336.20M	343.50M	347.84M	348.84M	350.99M	352.70M	355M	359.65M	362.04M	365.41M	367.93M
Normalized Net Operating Profit after Tax (NOPAT)	2,111	1,535	746	826	370	-68	553	842	949	1,100	1,125
Normalized NOPAT Margin	25.72%	14.69%	7.71%	9.47%	4.41%	-0.79%	0.00%	9.98%	11.68%	12.57%	11.69%
Pre Tax Income Margin	12.84%	-1.48%	-25.17%	-19.96%	-49.57%	-21.36%	0.00%	-12.14%	-1.59%	-4.45%	1.74%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.69	0.90	-0.33	0.11	-1.31	-0.12	0.41	0.31	0.76	0.69	1.10
NOPAT to Interest Expense	1.52	0.68	-0.22	0.04	-0.93	-0.09	0.30	0.21	0.54	0.51	-0.49
EBIT Less CapEx to Interest Expense	2.78	0.76	-0.46	0.02	-1.40	-0.28	0.22	0.13	0.39	0.52	0.85
NOPAT Less CapEx to Interest Expense	2.61	0.54	-0.34	-0.05	-1.01	-0.25	0.11	0.03	0.17	0.35	-0.74
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.91%	-3.13%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.91%	-28.13%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Bausch Health Companies' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-3.08%	-0.14%	1.36%	10.17%	9.38%	9.80%	10.75%	10.89%	12.15%	6.27%	4.92%
EBITDA Growth	-37.70%	-83.09%	-23.14%	27.76%	-44.74%	471.20%	25.25%	1.67%	100.60%	23.11%	-0.97%
EBIT Growth	-56.50%	-168.32%	-40.65%	136.97%	-97.21%	240.32%	61.21%	-3.32%	4,442.86%	54.31%	2.26%
NOPAT Growth	-55.87%	-113.13%	-38.60%	24.94%	-95.62%	253.39%	60.57%	-105.76%	2,171.43%	3.25%	-1.78%
Net Income Growth	110.99%	-669.44%	-216.67%	119.42%	-194.79%	88.54%	63.16%	-103.70%	75.92%	308.51%	-11.69%
EPS Growth	111.54%	-638.10%	-189.47%	117.50%	-193.64%	90.27%	69.09%	-57.14%	77.67%	318.18%	5.88%
Operating Cash Flow Growth	-323.94%	1,879.17%	344.44%	67.48%	122.33%	-17.89%	37.01%	84.47%	43.62%	54.10%	0.00%
Free Cash Flow Firm Growth	-119.01%	-103.64%	-68.78%	506.37%	58.19%	-398.10%	-261.25%	-144.38%	444.06%	340.64%	279.83%
Invested Capital Growth	4.09%	-0.19%	-1.46%	-5.48%	1.25%	4.31%	4.33%	2.84%	-3.04%	-5.86%	-4.88%
Revenue Q/Q Growth	4.02%	7.18%	-11.35%	11.47%	3.28%	7.60%	-10.59%	11.61%	4.45%	1.95%	-11.72%
EBITDA Q/Q Growth	8.19%	-79.44%	296.00%	45.05%	-53.20%	112.50%	-13.17%	17.74%	-7.67%	30.42%	-30.15%
EBIT Q/Q Growth	52.12%	-198.80%	166.53%	136.97%	-98.21%	4,871.43%	-23.56%	42.11%	-15.87%	68.87%	-49.35%
NOPAT Q/Q Growth	98.75%	-173.75%	174.15%	14.95%	-93.04%	2,485.71%	-22.38%	-104.12%	2,846.74%	17.54%	-26.16%
Net Income Q/Q Growth	389.93%	-201.74%	49.02%	112.92%	-1,514.81%	87.70%	-63.83%	98.70%	-9,100.00%	206.52%	-187.76%
EPS Q/Q Growth	375.00%	-202.73%	51.33%	112.73%	-1,571.43%	89.32%	-54.55%	117.65%	-866.67%	204.35%	-166.67%
Operating Cash Flow Q/Q Growth	-1,126.83%	137.61%	-67.58%	33.77%	36.89%	38.30%	-45.90%	80.09%	6.58%	48.40%	-64.89%
Free Cash Flow Firm Q/Q Growth	-88.06%	79.24%	434.79%	210.96%	-119.35%	-147.29%	-8.38%	14.41%	249.99%	72.95%	-19.00%
Invested Capital Q/Q Growth	-1.20%	-3.26%	-0.95%	-0.16%	5.83%	-0.33%	-0.93%	-1.58%	-0.23%	-3.23%	0.10%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	71.46%	70.27%	70.06%	70.05%	72.16%	70.72%	70.27%	70.08%	72.27%	71.59%	68.97%
EBITDA Margin	29.72%	5.70%	25.46%	33.13%	15.01%	29.65%	28.80%	30.38%	26.85%	34.35%	27.18%
Operating Margin	11.93%	-10.76%	9.00%	19.01%	0.63%	15.03%	13.05%	16.19%	12.67%	21.81%	12.22%
EBIT Margin	12.27%	-11.31%	8.49%	18.04%	0.31%	14.45%	12.35%	15.73%	12.67%	20.98%	12.04%
Profit (Net Income) Margin	19.70%	-18.70%	-10.75%	1.25%	-17.07%	-1.95%	-3.58%	-0.04%	-3.67%	3.83%	-3.81%
Tax Burden Percent	91.80%	114.85%	153.68%	34.18%	117.18%	671.43%	111.59%	-2.08%	438.10%	46.89%	182.98%
Interest Burden Percent	174.90%	143.95%	-82.42%	20.20%	-4,657.14%	-2.01%	-25.94%	12.70%	-6.60%	38.92%	-17.28%
Effective Tax Rate	8.20%	0.00%	0.00%	65.82%	0.00%	0.00%	0.00%	102.08%	0.00%	53.11%	0.00%
Return on Invested Capital (ROIC)	0.00%	-2.99%	2.52%	2.61%	0.18%	4.41%	3.96%	-0.15%	3.98%	4.75%	4.03%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-4.19%	0.89%	2.05%	-1.67%	2.97%	2.64%	-0.12%	2.51%	3.97%	2.69%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-755.23%	9,100.85%	161.05%	-358.15%	693.48%	-3,765.62%	-108.62%	-224.36%	-410.92%	-271.20%
Return on Equity (ROE)	181.21%	-758.22%	9,103.37%	163.65%	-357.98%	697.89%	-3,761.67%	-108.77%	-220.38%	-406.17%	-267.17%
Cash Return on Invested Capital (CROIC)	-0.44%	1.74%	2.65%	-15.97%	-0.04%	-0.99%	-0.63%	0.77%	7.57%	2.82%	1.80%
Operating Return on Assets (OROA)	0.00%	-3.35%	2.54%	5.61%	0.10%	4.77%	4.23%	5.57%	4.48%	7.50%	4.39%
Return on Assets (ROA)	0.00%	-5.53%	-3.21%	0.39%	-5.46%	-0.64%	-1.22%	-0.01%	-1.30%	1.37%	-1.39%
Return on Common Equity (ROCE)	-443.29%	2,677.25%	-2,312,255.81%	-423.50%	3,082.56%	-6,720.13%	-248,399.75%	4,543.69%	-1,087.57%	-2,313.37%	-1,482.98%
Return on Equity Simple (ROE_SIMPLE)	-51.43%	0.00%	44.38%	28.51%	82.54%	0.00%	42.96%	43.15%	18.48%	0.00%	6.85%
Net Operating Profit after Tax (NOPAT)	224	-165	123	141	9.80	253	197	-8.10	223	262	193
NOPAT Margin	10.95%	-7.53%	6.30%	6.50%	0.44%	10.52%	9.14%	-0.34%	8.87%	10.22%	8.55%
Net Nonoperating Expense Percent (NNEP)	-0.87%	1.20%	1.62%	0.55%	1.85%	1.44%	1.32%	-0.03%	1.48%	0.78%	1.34%
Return On Investment Capital (ROIC_SIMPLE)	-	-0.79%	-	-	-	1.14%	-	-	-	1.23%	0.91%
Cost of Revenue to Revenue	28.54%	29.73%	29.94%	29.95%	27.84%	29.28%	29.73%	29.92%	27.73%	28.41%	31.03%
SG&A Expenses to Revenue	32.31%	30.37%	37.29%	32.81%	31.95%	31.81%	36.88%	34.62%	33.86%	32.04%	38.38%
R&D to Revenue	6.50%	6.48%	7.36%	7.20%	6.84%	6.31%	7.01%	6.49%	5.82%	6.37%	6.33%
Operating Expenses to Revenue	59.53%	81.03%	61.06%	51.04%	71.54%	55.69%	57.22%	53.89%	59.60%	49.79%	56.75%
Earnings before Interest and Taxes (EBIT)	251	-248	165	391	7.00	348	266	378	318	537	272
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	608	125	495	718	336	714	620	730	674	879	614
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.28	0.36	0.35	0.35	0.33	0.43	0.28	0.32	0.31	0.24
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.14	1.14	1.18	1.18	1.19	1.19	1.24	1.18	1.19	1.21	1.18
Enterprise Value to Revenue (EV/Rev)	0.00	2.88	2.94	2.85	3.00	2.89	2.91	2.67	2.61	2.53	2.43
Enterprise Value to EBITDA (EV/EBITDA)	9.47	12.08	13.41	12.23	15.29	11.18	10.94	10.23	9.02	8.38	8.17
Enterprise Value to EBIT (EV/EBIT)	22.87	52.53	72.07	42.59	81.24	27.77	25.82	24.57	18.84	16.24	15.73
Enterprise Value to NOPAT (EV/NOPAT)	32.66	73.71	99.67	0.00	100.16	37.52	34.93	33.52	26.12	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	22.91	24.51	24.00	19.43	17.81	15.24	14.83
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	65.66	44.38	0.00	0.00	0.00	0.00	156.12	15.46	41.64	63.72
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	49.00	79.87	142.43	75.84	-95.45	-273.02	-126.86	-95.42	-88.87	-67.13	-89.63
Long-Term Debt to Equity	48.05	78.21	139.36	74.20	-93.17	-267.54	-123.77	-93.43	-87.00	-58.83	-88.45
Financial Leverage	138.16	180.25	10,207.50	78.47	213.98	233.87	-1,429.00	931.84	-89.42	-103.57	-100.66
Leverage Ratio	186.41	242.87	13,633.75	102.43	269.51	297.96	-1,805.45	1,181.77	-112.38	-133.35	-128.83
Compound Leverage Factor	326.03	349.61	-11,237.52	20.70	-12,551.24	-5.99	468.33	150.07	7.42	-51.90	22.26
Debt to Total Capital	98.00%	98.76%	99.30%	98.70%	101.06%	100.37%	100.79%	101.06%	101.14%	101.51%	101.13%
Short-Term Debt to Total Capital	1.90%	2.05%	2.14%	2.13%	2.42%	2.02%	2.46%	2.11%	2.13%	12.56%	1.33%
Long-Term Debt to Total Capital	96.10%	96.71%	97.16%	96.57%	98.64%	98.35%	98.34%	98.95%	99.01%	88.95%	99.80%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	4.43%	4.53%	4.54%	4.49%	4.26%	4.21%	4.30%	4.42%	4.38%	4.49%	4.43%
Common Equity to Total Capital	-2.43%	-3.29%	-3.85%	-3.18%	-5.32%	-4.58%	-5.09%	-5.48%	-5.52%	-6.01%	-5.56%
Debt to EBITDA	8.31	10.71	11.54	10.56	13.40	9.89	9.24	9.03	7.86	7.45	7.42
Net Debt to EBITDA	8.12	10.42	11.24	10.26	12.93	9.47	8.93	8.77	7.58	7.03	7.03
Long-Term Debt to EBITDA	8.15	10.49	11.29	10.33	13.08	9.69	9.02	8.84	7.69	6.53	7.33
Debt to NOPAT	28.67	65.34	85.77	-4.57	87.79	33.21	29.50	29.58	22.76	-32.43	-32.57
Net Debt to NOPAT	28.00	63.57	83.56	-4.44	84.74	31.78	28.49	28.73	21.97	-30.63	-30.82
Long-Term Debt to NOPAT	28.12	63.98	83.92	-4.47	85.69	32.54	28.78	28.96	22.28	-28.42	-32.14
Altman Z-Score	-0.38	-0.15	-0.09	-0.04	-0.09	-0.02	-0.02	-0.03	-0.02	-0.07	0.00
Noncontrolling Interest Sharing Ratio	344.63%	453.10%	25,500.00%	358.78%	961.11%	1,062.92%	-6,503.45%	4,277.27%	-393.50%	-469.55%	-455.07%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.05	1.08	1.08	1.12	1.20	1.30	1.23	1.19	1.19	0.86	1.35
Quick Ratio	0.58	0.60	0.56	0.59	0.64	0.68	0.63	0.62	0.62	0.49	0.75
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-608	-126	423	1,314	-254	-629	-681	-583	875	1,513	1,225
Operating Cash Flow to CapEx	-2,338.89%	719.70%	327.66%	735.71%	671.43%	397.96%	257.32%	487.18%	570.42%	566.98%	183.48%
Free Cash Flow to Firm to Interest Expense	0.00	-1.10	1.38	4.12	-0.75	-1.74	-1.98	-1.73	2.53	4.49	3.71
Operating Cash Flow to Interest Expense	0.00	4.13	0.50	0.65	0.83	1.08	0.61	1.12	1.17	1.78	0.64
Operating Cash Flow Less CapEx to Interest Expense	0.00	3.56	0.35	0.56	0.71	0.81	0.38	0.89	0.97	1.47	0.29
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.30	0.30	0.31	0.32	0.33	0.34	0.35	0.35	0.36	0.36
Accounts Receivable Turnover	0.00	4.56	5.01	4.93	4.63	4.62	4.80	4.79	4.69	4.65	4.72
Inventory Turnover	0.00	2.27	2.11	2.13	2.15	1.94	1.83	1.88	1.89	1.77	1.75
Fixed Asset Turnover	0.00	5.08	5.13	5.31	5.53	5.30	5.42	5.52	5.62	5.52	5.41
Accounts Payable Turnover	0.00	5.09	4.64	4.69	4.75	4.13	4.35	4.91	4.47	4.05	4.51
Days Sales Outstanding (DSO)	0.00	80.09	72.87	74.05	78.77	78.94	76.05	76.26	77.86	78.46	77.27
Days Inventory Outstanding (DIO)	0.00	160.81	172.75	171.11	169.54	187.85	199.31	193.71	193.54	205.92	208.56
Days Payable Outstanding (DPO)	0.00	71.64	78.64	77.75	76.83	88.43	83.89	74.30	81.73	90.20	81.01
Cash Conversion Cycle (CCC)	0.00	169.25	166.97	167.41	171.48	178.36	191.46	195.66	189.68	194.18	204.82
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	21,151	20,462	20,267	20,235	21,415	21,344	21,145	20,810	20,763	20,093	20,113
Invested Capital Turnover	0.00	0.40	0.40	0.40	0.40	0.42	0.43	0.45	0.45	0.46	0.47
Increase / (Decrease) in Invested Capital	832	-39	-300	-1,173	264	882	878	575	-652	-1,251	-1,032
Enterprise Value (EV)	24,168	23,427	24,000	23,808	25,590	25,295	26,135	24,542	24,685	24,336	23,677
Market Capitalization	2,492	2,273	2,933	2,910	2,995	2,929	3,875	2,557	2,996	2,964	2,381
Book Value per Share	($1.45)	($1.91)	($2.21)	($1.82)	($3.24)	($2.80)	($3.04)	($3.20)	($3.20)	($3.48)	($3.22)
Tangible Book Value per Share	($51.29)	($49.85)	($49.53)	($48.36)	($52.41)	($51.10)	($50.32)	($49.63)	($49.02)	($48.71)	($47.92)
Total Capital	21,648	21,026	20,798	20,823	22,195	22,306	21,900	21,433	21,265	21,294	21,270
Total Debt	21,215	20,766	20,653	20,552	22,430	22,388	22,074	21,660	21,507	21,616	21,510
Total Long-Term Debt	20,804	20,334	20,207	20,108	21,894	21,938	21,536	21,208	21,054	18,942	21,228
Net Debt	20,718	20,202	20,122	19,964	21,650	21,426	21,319	21,037	20,757	20,415	20,353
Capital Expenditures (CapEx)	54	66	47	28	42	98	82	78	71	106	115
Debt-free, Cash-free Net Working Capital (DFCFNWC)	93	174	229	350	580	782	774	671	548	495	601
Debt-free Net Working Capital (DFNWC)	590	738	760	938	1,360	1,744	1,529	1,294	1,298	1,696	1,758
Net Working Capital (NWC)	179	306	314	494	824	1,294	991	842	845	-978	1,476
Net Nonoperating Expense (NNE)	-179	245	332	114	392	300	274	-7.10	315	164	279
Net Nonoperating Obligations (NNO)	20,718	20,202	20,122	19,964	21,650	21,426	21,319	21,037	21,005	20,415	20,353
Total Depreciation and Amortization (D&A)	357	373	330	327	329	366	354	352	356	342	342
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	2.14%	2.81%	4.19%	6.79%	8.93%	8.63%	7.29%	5.78%	5.14%	6.18%
Debt-free Net Working Capital to Revenue	0.00%	9.08%	9.33%	11.23%	15.92%	19.92%	17.05%	14.06%	13.70%	17.62%	18.07%
Net Working Capital to Revenue	0.00%	3.77%	3.85%	5.92%	9.65%	14.78%	11.05%	9.15%	8.92%	-10.16%	15.17%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.10	($1.13)	($0.55)	$0.07	($1.03)	($0.11)	($0.17)	$0.03	($0.23)	$0.24	($0.16)
Adjusted Weighted Average Basic Shares Outstanding	362.50M	362M	363.30M	364.80M	365.40M	364.90M	366.80M	367.90M	368.40M	368M	369.60M
Adjusted Diluted Earnings per Share	$1.10	($1.13)	($0.55)	$0.07	($1.03)	($0.11)	($0.17)	$0.03	($0.23)	$0.24	($0.16)
Adjusted Weighted Average Diluted Shares Outstanding	363.40M	362M	363.30M	367.10M	365.40M	364.90M	366.80M	370.20M	368.40M	368M	369.60M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	361.87M	362.04M	363.72M	364.33M	365.20M	365.41M	366.80M	367.10M	367.80M	367.93M	369.55M
Normalized Net Operating Profit after Tax (NOPAT)	343	274	139	326	304	333	206	284	223	412	194
Normalized NOPAT Margin	16.78%	12.48%	7.13%	15.02%	13.57%	13.81%	9.56%	11.83%	8.90%	16.08%	8.58%
Pre Tax Income Margin	21.46%	-16.28%	-7.00%	3.65%	-14.57%	-0.29%	-3.20%	2.00%	-0.84%	8.17%	-2.08%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-2.16	0.54	1.23	0.02	0.96	0.77	1.12	0.92	1.59	0.82
NOPAT to Interest Expense	0.00	-1.44	0.40	0.44	0.03	0.70	0.57	-0.02	0.64	0.78	0.59
EBIT Less CapEx to Interest Expense	0.00	-2.73	0.38	1.14	-0.10	0.69	0.53	0.89	0.71	1.28	0.48
NOPAT Less CapEx to Interest Expense	0.00	-2.01	0.25	0.35	-0.10	0.43	0.33	-0.25	0.44	0.46	0.24
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Bausch Health Companies' Financials

When does Bausch Health Companies's fiscal year end?

According to the most recent income statement we have on file, Bausch Health Companies' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Bausch Health Companies' net income changed over the last 10 years?

Bausch Health Companies' net income appears to be on an upward trend, with a most recent value of -$72 million in 2024, falling from $880 million in 2014. The previous period was -$611 million in 2023. Check out Bausch Health Companies' forecast to explore projected trends and price targets.

What is Bausch Health Companies's operating income?

Bausch Health Companies's total operating income in 2024 was $1.55 billion, based on the following breakdown:

Total Gross Profit: $6.84 billion
Total Operating Expenses: $5.30 billion

How has Bausch Health Companies revenue changed over the last 10 years?

Over the last 10 years, Bausch Health Companies' total revenue changed from $8.21 billion in 2014 to $9.63 billion in 2024, a change of 17.3%.

How much debt does Bausch Health Companies have?

Bausch Health Companies' total liabilities were at $26.85 billion at the end of 2024, a 2.1% decrease from 2023, and a 28.4% increase since 2014.

How much cash does Bausch Health Companies have?

In the past 10 years, Bausch Health Companies' cash and equivalents has ranged from $322.60 million in 2014 to $3.24 billion in 2019, and is currently $1.18 billion as of their latest financial filing in 2024.

How has Bausch Health Companies' book value per share changed over the last 10 years?

Over the last 10 years, Bausch Health Companies' book value per share changed from 15.73 in 2014 to -3.48 in 2024, a change of -122.1%.

Related Companies

This page (NYSE:BHC) was last updated on 5/7/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch Health Companies (BHC) Financials

Frequently Asked Questions About Bausch Health Companies' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch Health Companies (BHC) Financials

Annual Income Statements for Bausch Health Companies

Quarterly Income Statements for Bausch Health Companies

Annual Cash Flow Statements for Bausch Health Companies

Quarterly Cash Flow Statements for Bausch Health Companies

Annual Balance Sheets for Bausch Health Companies

Quarterly Balance Sheets for Bausch Health Companies

Annual Metrics and Ratios for Bausch Health Companies

Quarterly Metrics and Ratios for Bausch Health Companies

Frequently Asked Questions About Bausch Health Companies' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools